Evidence map›Paper›PMID 40126701›Full record

ArticleNeurogenetics2025

Repeated clear benefits of immunotherapy in a patient with Charcot-Marie-Tooth disease carrying a rare point mutation in PMP22.

Honami Kawai, Yoichiro Nishida, Takashi Kanda, Takanori Yokota

Abstract readCase Reports
In one paragraph

Article in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Honami KawaiDepartment of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0002-9678-5660
Yoichiro NishidaDepartment of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan. y-nishida.nuro@tmd.ac.jp.ORCID http://orcid.org/0000-0001-6158-9355
Takashi KandaDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Yamaguchi, 755-8505, Japan.ORCID http://orcid.org/0000-0001-8919-6377
Takanori YokotaDepartment of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0002-6490-3263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a unique patient who had been diagnosed with inflammatory demyelinating polyneuropathy (CIDP) for 13 years with frequent clear responses to immunotherapies and was finally diagnosed with Charcot-Marie-Tooth disease (CMT) with a rare point mutation in PMP22 (c.320G > A, p.G107D). Some patients diagnosed with young-onset CIDP may have underlying CMT, and extensive genetic testing including point mutations of PMP22 gene is required not to miss the diagnosis.

Indexed as

Charcot-Marie-Tooth DiseaseImmunotherapyMyelin ProteinsPoint MutationFemaleHumansPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingYoung AdultMyelin ProteinsPMP22 protein, humanCharcot-Marie-Tooth disease (CMT)Chronic inflammatory demyelinating polyneuropathy (CIDP)Optic neuritisPMP22Point mutation

Identifiers

PMID40126701
PMCPMC11933163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.